AMOYTOP(SH:688278)2023-11-02 09:12Group 1: R&D Investment - The company plans to maintain a relatively high level of R&D investment within a manageable range to address more clinical issues [2]. Group 2: Clinical Cure Rates - As of June 30, 2023, the "Everest Project" has enrolled 31,037 chronic hepatitis B patients, achieving clinical cures in 5,681 cases, with a clinical cure rate of 33.2% for patients who completed 48 weeks of treatment [2][3]. Group 3: Chronic Hepatitis B Statistics - According to the "Guidelines for the Prevention and Treatment of Chronic Hepatitis B" (2022 edition), there are approximately 86 million chronic hepatitis B carriers in China [3]. - The majority of patients receiving treatment with Peginterferon have surface antigens below 1500 IU/ml [3]. Group 4: Long-acting Growth Hormone - The company is conducting clinical research on a PEGylated recombinant human growth hormone injection for treating idiopathic short stature in children [3].